Lyka Labs Limited (NSE:LYKALABS)
India
· Delayed Price · Currency is INR | Market Cap | 4.01B |
| Revenue (ttm) | 1.38B |
| Net Income (ttm) | 80.12M |
| Shares Out | 35.69M |
| EPS (ttm) | 2.22 |
| PE Ratio | 50.55 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,073 |
| Average Volume | 79,470 |
| Open | 112.16 |
| Previous Close | 112.23 |
| Day's Range | 112.16 - 114.75 |
| 52-Week Range | 96.80 - 176.59 |
| Beta | 0.55 |
| RSI | 43.29 |
| Earnings Date | Aug 1, 2025 |
About Lyka Labs
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-mal... [Read more]
Financial Performance
Financial StatementsNews
Lyka Labs secures patent for Pregabalin Gel 8% to treat diabetic neuropathic pain
Lyka Labs Limited has announced the grant of an Indian patent for its innovative topical product, Pregabalin Gel 8%, with protection extending until 2043. This milestone underscores Lyka Labs’ commitm...